Abbott

Piramal Healthcare to acquire Decision Resources Group

Thursday, May 17, 2012 10:04 AM

Piramal Healthcare, a pharmaceutical custom manufacturing company, has agreed to acquire Decision Resources Group (DRG), a healthcare information company of Burlington, Mass., from Providence Equity Partners for approximately $635 million.

More... »

Abbott, Syngene to open first nutrition R&D center in India

Friday, May 4, 2012 08:01 AM

Abbott, one of India's largest health care companies, is collaborating with Syngene, an Indian CRO and subsidiary of Biocon, to establish its first nutrition R&D center in the country.

More... »

Abbott, St. Jude Medical broaden alliance for cardiovascular products

Monday, April 23, 2012 02:16 PM

Global pharmaceutical company Abbott and St Jude Medical of St. Paul, Minn., have collaborated on the Choice Alliance, a multi-year joint initiative that provides mutual U.S. customers access to a robust portfolio of interventional cardiology, electrophysiology and intravascular imaging, cardiac rhythm management and diagnostic technologies.

More... »

Report: Pharmaceutical market grew by 5.3% in 2011

Friday, April 20, 2012 12:29 PM

Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, found that in 2011, the global pharmaceutical market, in dollar terms, benefitted significantly from positive currency effects.

More... »

Abbott touts positive results in phase III Parkinson's trial

Wednesday, April 18, 2012 03:39 PM

Abbott has released results from a phase III trial evaluating the company's investigational compound, levodopa-carbidopa intestinal gel (LCIG), for advanced Parkinson's disease.

More... »

Syndax appoints Pappas to board of directors

Friday, April 6, 2012 03:26 PM

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company based in Waltham, Mass., has added Arthur M. Pappas to the ranks of its board of directors.

More... »

Abbott touts promising results in phase II Hep C trial

Thursday, April 5, 2012 08:00 AM

Abbott has released promising data from two different interferon-free phase II studies for hepatitis C (HCV), suggesting that a 12-week regimen of two Abbott medicines, and no peginterferon, can achieve high cure rates for treatment-naïve, genotype 1 patients.

More... »

Abbott selects “AbbVie” as new name for future pharma company

Thursday, March 22, 2012 06:30 AM

Abbott has dubbed its new, independent research-based pharmaceutical company AbbVie (pronounced Abb-vee), which it will launch by the end of 2012.

More... »

Abbott and Galapagos collaborate on autoimmune diseases

Friday, March 2, 2012 07:39 AM

Abbott and Galapagos, a biotechnology company based in Belgium, have entered into a global collaboration to develop and commercialize an oral, next-generation JAK1 inhibitor (GLPG0634) in phase II development with the potential to treat multiple autoimmune diseases.

More... »

Abbott, Reata Pharmaceuticals ink $400 million agreement

Monday, December 12, 2011 01:38 PM

Abbott and Reata Pharmaceuticals have entered into a worldwide collaboration to jointly develop and commercialize Reata's portfolio of second-generation oral antioxidant inflammation modulators (AIMs). The agreement is in addition to the partnership between the two companies formed in September 2010 in which Reata granted to Abbott exclusive rights to develop and commercialize its lead AIM compound, bardoxolone methyl, outside of the United States, excluding certain Asian markets.

More... »